Advanced in Multiple System Atrophy

Toshio Shimizu

Fuchu, JP 
Advanced in Multiple System Atrophy
Fuchu, JP 
OverviewLocationsClinical Research

Overview

Toshio Shimizu practices in Fuchu, Japan. Mr. Shimizu is rated as an Advanced expert by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Lung Cancer, Gastrostomy, and Endoscopy.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Multiple System Atrophy.

Gender
Male

Locations

Fuchu, Japan
Other Locations
Wakayama, Japan
Tokyo, Japan
Osaka, Japan
Chuo, 1040045, Japan
Horinouchi, Japan
Hachioji, 1920397, Japan
Saitama, Japan
Sayama, 5770818, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation
A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation
Enrollment Status: Terminated
Publish Date: November 24, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

151 Total Publications

Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes.
Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes.
Journal: International journal of clinical oncology
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shimizu's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile